| Project/Area Number |
21592167
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWAHARA Katsumasa 北里大学, 医学部, 教授 (70134525)
SAKAGAMI Hiroyuki 北里大学, 医学部, 教授 (90261528)
|
|---|
| Project Period (FY) |
2009 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | Arg-vasopressin / Meniere's disease / V2R antagonist / V1aR antagonist / hydration therapy / Arg-Vasopressin / 血管条 / 中間細胞 / 液胞 / 内リンパ水腫 / 聴力低下 / 酸素分圧 / メニエール病 / 浮腫 |
|---|
| Research Abstract |
Wistar rats were intraperitoneally injected 0.02 units/g of AVP (Pitressin; Arg-vasopressin. Daiichi-Sankyo, Japan)in the all experiments in this study. ABR thresholds gradually increased significantly upto 60 min after the injection. When the dehydration load pretreatment for 24h was added, ABR thresholds rapidly increased significantly up to 10 min after the injection. However, the morphological endolymphatic hydrops in cochlea was not detected under a light microscopy. However, the enlargement of an area lacking intracellular organelles in the intermediate cells in stria vascularis or a so called “vacuole” was detected under transmission electron microscopy after the AVP injection. When the dehydration load pretreatment for 24h was added, the vacuole area increased with AVP injection. However, when the V2Rantagonist (OPC-31260, donated by Otsuka Pharmaceutical) was administered before AVP,vacuole formation was suppressed significantly. Conversely, vacuole formation was not suppressed when the V1aR antagonist (OPC-21268, donated by Otsuka Pharmaceutical) was administered before AVP injection.
|
